Sign up to save your podcasts
Or
Share JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
JAMA Oncology : Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
View all episodes
By The JAMA Network
4.9
1212 ratings
Interview with Robert J. Motzer, MD, author of Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. Hosted by Jack West, MD.
More shows like JAMA Network
View all
JAMA Editors' Summary
134 Listeners
Medicine and Science from The BMJ
41 Listeners
NEJM This Week
315 Listeners
Diabetes Core Update
106 Listeners
JAMA Clinical Reviews
498 Listeners
AFP: American Family Physician Podcast
689 Listeners
JAMA Pediatrics Editors' Summary
38 Listeners
Mayo Clinic Talks
279 Listeners
The Curbsiders Internal Medicine Podcast
3,331 Listeners
JAMA Dermatology Author Interviews
17 Listeners
JAMA Internal Medicine Author Interviews
18 Listeners
JAMA Neurology Author Interviews
13 Listeners
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
6 Listeners
JAMA Medical News
90 Listeners
Core IM | Internal Medicine Podcast
1,107 Listeners
JAMAevidence The Rational Clinical Examination
29 Listeners
Annals On Call Podcast
197 Listeners
The Clinical Problem Solvers
517 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
350 Listeners
Cardionerds: A Cardiology Podcast
426 Listeners
JAMAevidence JAMA Guide to Statistics and Methods
18 Listeners
The Curious Clinicians
368 Listeners
NEJM AI Grand Rounds
53 Listeners